Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when CATX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPerspective Therapeutics discloses preliminary Q1 2026 cash position in analyst presentation
Filed May 4, 2026 · Period ending May 4, 2026 · ~1 min read
Key Changes
-
medium
Company disclosed preliminary, unaudited cash and short-term investments as of March 31, 2026 in a presentation posted to its website. The independent auditor has not reviewed these figures.
Item 7.01 view on EDGAR → -
medium
Actual Q1 2026 results may differ from preliminary data due to ongoing quarter-end closing procedures, final adjustments, and other developments arising before financial results are finalized.
Item 7.01 view on EDGAR → -
low
The 8-K filing serves to make the analyst presentation publicly available; no other material business events were disclosed.
Item 7.01 view on EDGAR →
Summary
Perspective Therapeutics filed an 8-K to disclose preliminary financial data shared in an analyst presentation posted May 4, 2026. The presentation includes estimated cash, cash equivalents, and short-term investments as of March 31, 2026, but these figures are unaudited and have not been reviewed by the company's independent auditor, Withum. Retail investors should treat these preliminary numbers with caution.
The company explicitly warned that actual Q1 results may differ due to ongoing closing procedures, final adjustments, and other developments. Any material variance could signal accounting complexities or unexpected quarter-end adjustments worth understanding.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Added in current filing · verify on EDGAR →
The Company’s actual results as of March 31, 2026 may differ from the preliminary financial data due to the completion of the Company’s closing procedures with respect to the quarter ended March 31, 2026, final adjustments and other developments that may arise between now and the time the financial results for the such fiscal quarter are finalized.
The company explicitly cautioned that actual Q1 2026 results may differ from the preliminary figures disclosed in the presentation due to ongoing quarter-end closing procedures, final adjustments, and other developments. Investors should treat the preliminary cash position as subject to revision.
Event · Item 8.01 — Other Events
Company posted a presentation to its website on May 4, 2026.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On May 4, 2026, the Company posted the Presentation to its website.
The company disclosed that it posted a presentation to its website on May 4, 2026. The presentation is filed as Exhibit 99.1. Without access to the actual presentation content, the materiality and investor relevance cannot be determined from this procedural disclosure alone.
Event · Item 9.01 — Financial Statements and Exhibits
Perspective Therapeutics filed an 8-K attaching a company presentation with no material business event disclosed.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Exhibit No. | Description | 99.1 | Company Presentation.
The company filed an 8-K solely to attach a company presentation as Exhibit 99.1. No specific corporate event, financial result, or material business development is disclosed in the body of the filing. This is a routine procedural filing to make a presentation publicly available.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify